In patients with heart failure, absolute benefits of SGLT2 inhibitor treatment on the outcome of cardiovascular death or hospitalisation for heart failure were notably large, irrespective of diabetes status (figure 5). This evidence concerns the gene SLC5A2 and heart failure.